WC
ESPR icon

Wexford Capital’s Esperion Therapeutics ESPR Stock Holding History

Wexford Capital’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-1,477
Closed -$38K – 252
2020
Q4 		$38K Buy
+1,477
New +$44.2K 0.01% 272

Other funds holding ESPR

WA
Wasatch Advisors Salt Lake City, Utah $13.5B AUM 16.58% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
MG
Meditor Group Hamilton, Bermuda $48.1M AUM 38.67% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
PIM
Platinum Investment Management Sydney Australia 2000, Australia $407M AUM 87.11% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return

Wexford Capital's ESPR Position: Q1 2021 in Review

Wexford Capital sold out of Esperion Therapeutics (ESPR) in Q1 2021, closing a stake of 1,477 shares — an estimated $38K sold.

Wexford Capital first reported a position in ESPR in Q4 2020 and held it in 1 quarter. The position peaked at $38K in Q4 2020. 156 funds tracked by Wall St. Rank hold ESPR as of Q1 2021.

  • Wexford Capital reported no remaining Esperion Therapeutics position as of Q1 2021 after selling out during the quarter.
  • Wexford Capital sold 1,477 Esperion Therapeutics shares in Q1 2021, an estimated $38K.
  • Wexford Capital first reported a position in Esperion Therapeutics in Q4 2020 and held it in 1 quarter.
  • Wexford Capital's Esperion Therapeutics position peaked at $38K in Q4 2020.
  • 156 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q1 2021.

Based on Wexford Capital's 13F filing for Q1 2021, filed 13 May 2021.